Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding phase II study of CP-4055 plus sorafenib in metastatic malignant melanoma
2007-000915-28Phase 2Completed
- Sponsor
- Clavis Pharma
- Start
- Mar 2007
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of elacytarabine and sorafenib in melanoma, sponsored by Clavis Pharma. Primary endpoint: Objective tumor response. Started Mar 2007; status: completed.
02
Drugs
elacytarabinesorafenib
03
Conditions
melanoma
Beyond the preview
Go deeper on 2007-000915-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000915-28.